159
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

CD38 is a potential treatment target in lymphoma patients concurrently infected with human immunodeficiency virus

ORCID Icon, , , , , , , ORCID Icon, , , & ORCID Icon show all
Pages 1479-1483 | Received 08 Sep 2021, Accepted 19 Dec 2021, Published online: 12 Jan 2022

References

  • Noy A. Optimizing treatment of HIV-associated lymphoma. Blood. 2019;134(17):1385–1394.
  • Gibson TM, Morton LM, Shiels MS, et al. Risk of non-Hodgkin lymphoma subtypes in HIV-infected people during the HAART era: a population-based study. AIDS. 2014;28(15):2313–2318.
  • Re A, Cattaneo C, Rossi G. Hiv and lymphoma: from epidemiology to clinical management. Mediterr J Hematol Infect Dis. 2019;11(1):e2019004.
  • Lewden C, May T, Rosenthal E, ANRS EN19 Mortalité Study Group and Mortavic1, et al. Changes in causes of death among adults infected by HIV between 2000 and 2005: the “ "Mortalité 2000 and 2005" surveys (ANRS EN19 and Mortavic)”. J Acquir Immune Defic Syndr. 2008;48(5):590–598.
  • Smith CJ, Ryom L, Weber R, D:A:D Study Group, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–248.
  • Vase MØ, Ludvigsen M, Bendix K, et al. Proteomic profiling of pretreatment serum from HIV-infected patients identifies candidate markers predictive of lymphoma development. AIDS. 2016;30(12):1889–1898.
  • Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the world health organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–2390.
  • Hybel TE, Vase MØ, Maksten EF, et al. Intratumoral expression of CD38 in patients with post-transplant lymphoproliferative disorder. Acta Oncol (Madr) [Internet]. 2021; 60:1–6. https://doi.org/10.1080/0284186X.2021.1973093
  • Hoffmann C, Tiemann M, Schrader C, et al. AIDS-related B-cell lymphoma (ARL): correlation of prognosis with differentiation profiles assessed by immunophenotyping. Blood. 2005;106(5):1762–1769.
  • Koizumi Y, Uehira T, Ota Y, et al. Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases. Int J Hematol. 2016;104(6):669–681.
  • Calabretta E, Carlo-Stella C. The many facets of CD38 in lymphoma: from Tumor-Microenvironment cell interactions to acquired resistance to. Immunotherapy. Cells. 2020;9(4):802.
  • Savarino A, Bottarel F, Malavasi F, et al. Role of CD38 in HIV-1 infection: an epiphenomenon of T-cell activation or an active player in virus/host interactions? AIDS. England. 2000;14:1079–1089.
  • Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis. 1999;179(4):859–870.
  • D’Agostino M, Innorcia S, Boccadoro M, et al. Monoclonal antibodies to treat multiple myeloma: a dream come true. Int J Mol Sci. 2020;21:21.
  • Tan CR, Barta SK, Lensing SY, et al. A multicenter, Open-Label feasibility study of daratumumab with Dose-Adjusted EPOCH in newly diagnosed plasmablastic lymphoma: AIDS malignancy consortium 105. Blood [Internet]. 2019;134(Supplement_1):1595–1595. https://doi.org/10.1182/blood-2019-129702

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.